Skip to main content
SpringerLink
Log in

Präkursoren

  • Chapter
Neuro-Psychopharmaka

  • 43 Accesses

Zusammenfassung

Unter Aminpräkursoren werden die biologischen Vorstufen von Monoamin Neurotransmittern verstanden. Es handelt sich um einige Aminosäuren und Cholin, welche in Form der Proteine und als Lezithin (Phosphatidylcholin) mit der normalen menschlichen Nahrung aufgenommen werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Barbeau A, Growdon J, Wurtman R (eds) (1979) Cholin and lecithin in brain disorders. Raven Press, New York (Nutrition and the brain, vol 5 )

    Google Scholar 

  2. Beckmann H(1983) Phenylalanin in affective disorders. In: Van Praag HM, Mendlewicz J (eds)Management of depression with monoamine precursors. Karger, Basel, pp 137–147 (Adv Biol Psychiatry, vol 10 )

    Google Scholar 

  3. Benkert O, Hippius H(1986)Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  4. Boulton AA, Maitre L, Bieck PR, Riederer P (eds)(1985) Neuropsychopharmacology of the trace amines. Humana Press, Clifton

    Google Scholar 

  5. Cohen BM, Lipinski J, Altesman RI(1982)Lecithin in the treatment of ‘mania: double-blind, placebo-controlled trials. Am J Psychiatry 139:1162–1164

    PubMed  CAS  Google Scholar 

  6. Demisch L, Rother E(1987)Neurobiologische Aspekte von L-Tryptophan, Serotonin und verwandten Indolaminen. In: Demisch L (Hrsg) Therapie mit Präkursoren. Zuckschwerdt, München, S 45–63

    Google Scholar 

  7. Fernstrom JD(1983) Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 63: 484–546

    PubMed  CAS  Google Scholar 

  8. Kuhn DM, Wolf WA, Youdim Mbh(1986) Serotonin neurochemistry revisited: a new look at some old axioms. Neurochem Int 8: 141–154

    PubMed  CAS  Google Scholar 

  9. Sulser F,Mishra R(1983)The discovery of tricyclic antidepressants and their mode of action. In: Parnham Mj, Bruinvels J (eds) Discoveries in pharmacology, vol 1. Elsevier, Amsterdam, pp 209–222

    Google Scholar 

  10. Van Praag Hm, Mendlewicz J (eds)(1983) Manage- ment of depression with monoamine precur-sors. Karger, Basel (Adv Biol Psychiatry, vol 10) Weber IT Horita A (1965) A study of 5-hy- droxytryptamine formation from 1-tryptophan in the brain and other tissues. Biochem Pharmacol 14: 1141–1149

    Google Scholar 

  11. Zeller Ea(1983)Monoamine oxidase and its inhibitors in relation to antidepressive activity. In: Parnham MJ, Bruinvels J (eds) Discoveries in pharmacology, vol 1. Elsevier, Amsterdam, pp 223–232

    Google Scholar 

  12. Zipp F, Demisch L(1992)Aktuelles in der Diskussion um das Eosinophilie-Myalgie-Syndrom ( EMS ). Nervenarzt 63: 249–253

    Google Scholar 

  13. Agid Y,JAvoy F,Glowinski J(1973)Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature New Biology 245: 150–151

    PubMed  CAS  Google Scholar 

  14. ALousi A,Weiner N(1966)The regulation of norepinephrine synthesis in sympathetic nerves: nerve stimulation, cocaine and catecholamine releasing agents. Proc Natl Acad Sci USA 56: 1491–1496

    PubMed  CAS  Google Scholar 

  15. Ambrozi L,Riederer P, Birkmayer W, Neumayer E(1974)Zur Statistik des Tyrosin-TryptophanDiagramms bei der Depression. Dtsch Med Wochenschr 99 (20):1087–1089

    PubMed  CAS  Google Scholar 

  16. Ashcroft GW, Crawford TBB, Eccleston D, Sharman Df, Macdougall EJ, Stanton Jb,Binns Jk(1966) 5-Hydroxyindole compounds in the cerebral fluid of patients with psychiatric or neurological disorders. Lancet ii: 1049

    Google Scholar 

  17. Beckmann H(1982)Biochemische Beiträge zu Klassifikation und Therapievorhersage bei endogenen Depressionen. In: Beckmann H (Hrsg) Biologische Psychiatrie. G Thieme, Stuttgart New York, S 126–147

    Google Scholar 

  18. Birkmayer W, Hornykiewicz 0(1964)Weitere experimentelle Untersuchungen über L-Dopa beim Parkinson-Syndrom und Reserpin-Par-kinsonismus. Arch Psychiat Z Ges Neurol 206: 606–607

    Google Scholar 

  19. Bruinvels J(1975)Role of sodium in neuronal uptake of monoamines and amino acid precursors. Nature 257: 606–607

    PubMed  CAS  Google Scholar 

  20. Bruinvels J(1980)Sodium ion displacement as a regulatory factor in depolarization — induced catecholamine biosynthesis. In: Parvez H, parvez S (eds) Advances in experimental medicine: a centenary tribute to Claude Bernard. Elsevier/North-Holland Biomedical Press, Amsterdam, pp 557–577

    Google Scholar 

  21. Bruinvels J(1981)Transport systems for tyrosine and their relation to catecholamine biosynthesis. In: USDIN E et al. (eds) Function and regulation of monoamine enzymes: basic and clinical aspects. McMillan, London Basingstoke, pp 315–326

    Google Scholar 

  22. Coppen A, Shaw Dm, Farrell JP(1963)Potentiation of the antidepressant effect of a monoamine oxidase inhibitor by tryptophan. Lancet ii: 79–81

    Google Scholar 

  23. Diez-Guerra Fj, Gimenez C(1989)Na’ — Dependence of tyrosine transport across the synaptosomal membrane reflects changes in the morphology of synaptosomes. J Neurochem 52: 1366–1374

    Google Scholar 

  24. Ehringer H, Hornykiewicz 0(1960)Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239

    CAS  Google Scholar 

  25. Fernstrom JD(1979)Diet-induced changes in plasma amino acid pattern; effects on the brain uptake of large neutral amino acids, and on brain serotonin synthesis. J Neural Transm [Suppl] 15: 55–67

    CAS  Google Scholar 

  26. Fernstrom JD, Wurtman RJ(1971)Brain serotonin content: increase following ingestion of carbohydrate diet. Science 174: 1023–1025

    PubMed  CAS  Google Scholar 

  27. Fernstrom JD, Hirsch MJ, Faller D(1976)Tryptophan concentrations in rat brain; failure to correlate with free serum tryptophan or its ratio to the sum of other serum neutral amino acids. Biochem J 160: 589–595

    PubMed  CAS  Google Scholar 

  28. Goodwin FK, Cowdry R, Gold PW, Wehr T(1977)Central monoamine metabolism in depression and mania. In: VAN Praag HM, Bruinvels J (eds) Neurotransmission and disturbed behaviour. Bohn, Scheltema and Holkema, Utrecht, pp 34–59

    Google Scholar 

  29. Hamon M, Bourgoin S, Glowinski J(1974) Feedback regulation of 5-HT synthesis in rat striatal slices. J Neurochem 20: 1727

    Google Scholar 

  30. Harper AE, Tews JK(1988)Nutritional and metabolic control of brain amino acids. In: Huether G (ed) Amino acid availability and brain function in health and disease. Springer, Berlin Heidelberg New York Tokyo, pp 3–12 (Nato ASI Series H, 20 )

    Google Scholar 

  31. Jaquier E, Lovenberg W, Sjoerdsma A(1967)Tryptophan hydroxylase inhibition: the mechanism by which pchlorophenylalanine depletes rat brain serotonin. Mol Pharmacol 3: 274–278

    Google Scholar 

  32. Knott PJ, Curzon G(1972)Free tryptophan in plasma and brain tryptophan metabolism. Nature 239: 452–453

    PubMed  CAS  Google Scholar 

  33. Mackenzie Rg, Trulson Me(1978)Does insulin act directly on the brain to increase tryptophan levels? J Neurochem 30: 1205–1208

    Google Scholar 

  34. Mcgeer Eg, Peters Dav, Mcgeer PL(1968)Inhibition of rat brain tryptophan hydroxylase by 6-halotryptophans. Life Sci 7: 605–615

    PubMed  CAS  Google Scholar 

  35. Mc Menamy Rh, Oncleyjl (1958) Specific binding of L-tryptophan to serum albumin. J Biol Chem 233: 1436–1447

    Google Scholar 

  36. Nagatsu T, Levitt M, Udenfriend S (1964) Tyro-sine hydroxylase. J Biol Chem 239: 2910–2917

    PubMed  CAS  Google Scholar 

  37. Neumayer E, Riederer P, Danielczyk W,Seemann D(1975) Biochemische Hirnbefunde bei endogener Depression. Wien Med Wochenschr 21: 344–349

    Google Scholar 

  38. Oldendorf Wh(1971)Brain uptake of radio-labeled amino acids, amines and hexoses after arterial injection. Am J Physiol 221: 1629–1639

    Google Scholar 

  39. Riederer P, Birkmayer W(1993)Pathobiochemie bei Depressionen. 1. Alle Defizitmodelle sind heute überholt. Ärztl Praxis 45 (14): 27–29

    Google Scholar 

  40. Riederer P, Birkmayer W(1993)Pathobiochemie bei Depressionen. 2. Ungleichgewicht zwischen den Überträgersystemen ? Ärztl Praxis 45 (15): 26–30

    Google Scholar 

  41. Sedvall GC, Kopin Ij(1967)Acceleration of nor-epinephrine synthesis in the rat submaxillary gland in vivo during sympathetic nerve stimulation. Life Sci 6: 45–51

    PubMed  CAS  Google Scholar 

  42. Tagliamonte A, Biggio G, Gessa GL(1971)Possible role of free plasma tryptophan in controlling brain tryptophan concentration. Riv Farmacol Terapia 2: 251–255

    CAS  Google Scholar 

  43. Tagliamonte A, Biggio G, Vargui L, Gessa GL(1973)Free tryptophan in serum controls brain tryptophan level and serotonin synthesis. Life Sci 12 (II): 277–287

    CAS  Google Scholar 

  44. Udenfriend S, Saltzman-Nirenberg P,Nagatsu T(1965)Inhibition of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 14: 837–845

    PubMed  CAS  Google Scholar 

  45. VAN Praag Hm(1981) Management of depression with serotonin precursors. Biol Psychiatry 16: 291–310

    PubMed  Google Scholar 

  46. VAN Praag Hm, KoRF J, PUITE J(1970)5-hydroxyindoleacetic acid in the cerebrospinal fluid of depressive patients treated with probenecid. Nature 225: 1259–1260

    Google Scholar 

  47. Wade La, Katzman R(1975)Synthetic amino acids and the nature of L-DOPA transport at the blood brain barrier. J Neurochem 25: 837842

    Google Scholar 

  48. Weiner N(1970)Regulation of norepinephrine biosynthesis. Ann Rev Pharmacol 10: 273–290

    PubMed  CAS  Google Scholar 

  49. Weiner N, Bjur R, Lee Fl, Becker G, Mosimann F(1973)Studies on the mechanism of regulation of tyrosine hydroxylase activity during nerve stimulation. In: Usdin E, Snyder S (eds) Frontiers in catecholamine research. Perga-mon Press, New York, pp 211–221

    Google Scholar 

  50. Wilkinson LS, Collard KJ(1984)Opposite effects of extracellular sodium removal on the uptake of tryptophan into rat cortical slices and synaptosomes. J Neurochem 43: 274–275

    PubMed  CAS  Google Scholar 

  51. Wurtman Rf, Larin F, Mostafapour S, Fernstrom Jd(1974) Brain catechol synthesis: control by brain tyrosine concentration. Science 185: 183–184

    Google Scholar 

  52. Young Sn, Chouinard G, Annable L, Morand C,Ervin FR(1984) The therapeutic action of tryptophan in depression, mania and aggres-sion. In: Schlossberger HG, Kochen W, Linzen B, Steinhart H (eds) Progress in tryptophan and serotonin research. Gruyter, Berlin New York, pp 321–324

    Google Scholar 

  53. Zigmond J, Abercrombie ED, Berger 1W, Grace AA, Stricker EM(1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. TINS 13: 290–296

    CAS  Google Scholar 

  54. Angst J, Woggon B, Schoepf J (1977) The treatment of depression with 1–5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Arch Psychiatr Nervenkr 224: 175–186

    Google Scholar 

  55. Aylward M(1976) Presented on a meeting of the Royal College of Physicians Anonymus (1987) Eosinophilia-myalgia syndrome. New Mexico Morbid Mortal Wkly Rep 38: 765–767, 785

    Google Scholar 

  56. Barker A, Scott J, Eccleston D(1987) The Newcastle chronic depression study:results of a treatment regime. Int Clin Psychopharmacol 2: 261–272

    PubMed  CAS  Google Scholar 

  57. Barlet P, Paliard P(1974) Etude clinique du 5hydroxytryptophane dans les etats depressifs du troisieme age. Cah Med Lyonnais 50: 1895-1901

    Google Scholar 

  58. Beckmann H, Kasper S(1983)Serotonin-Vorstufen als Antidepressiva. Eine Ubersicht. Fortschr Neurol Psychiatr 51: 176–182

    Google Scholar 

  59. Belongia EA, Hedberg CW, Gleich Gj, White KE, Mayeno AN, Loegring DA, Dunette SL, Pirie PL, Macdonald KL, Osterholm MT(1990)An investigation of the cause of the eosinophiliamyalgia syndrome associated with tryptophan use. N Engl J Med 323: 357–365

    PubMed  CAS  Google Scholar 

  60. Boman B(1988)L-Tryptophan: a rational antidepressant and a natural hypnotic? Aust NZ J Psychiatry 22: 83–97

    CAS  Google Scholar 

  61. Brodie Hkh, Sack R, Siever L(1973)In: Barchas J, Usdin E (eds) Serotonin and behavior. Academic Press, New York, pp 549–559

    Google Scholar 

  62. Bunney We, Brodie Hkh, Murphy DL, Goodwin Fk(1971)Studies of a-methyl-p-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 127: 872–881

    Google Scholar 

  63. Chamberlain B, Ervin FR, Pihl RO, Young Sn(1987) The effect of raising or lowering tryp- tophan levels on aggression in vervet mon- keys. Pharmacol Biochem Behav 28: 503–510

    Google Scholar 

  64. Chouinard G, Young SN, Annable L, Sourkes TL(1979)Tryptophanicotinamide, imipramine and their combination in depression. Acta Psychiatr Scand 59: 395–414

    PubMed  CAS  Google Scholar 

  65. Chouinard G, Young SN, Annable L(1985)A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry 20: 546–557

    PubMed  CAS  Google Scholar 

  66. Cole Jo, Hartman E, Brigham P(1980)Ltryptophan:clinical studies. In: COLE JO (ed) Psychopharmacology update.The Collamore Press, Lexington Ma, pp 119–148

    Google Scholar 

  67. Conte Hr, Plutchik R(1974) Personality and background characteristics of suicidal mental patients. J Psychiatr Res 10: 181

    Google Scholar 

  68. Coppen A, SHAW DM, Farrel JP(1963) Potentiation of the antidepressive effect of a monoamineoxidase inhibitor by tryptophan. Lancet is 7881

    Google Scholar 

  69. Coppen A, Shaw Dm, Herzberg R, Maggs R(1967) Tryptophan in the treatment of depression. Lancet ii: 1178–1180

    Google Scholar 

  70. Coppen Aj, Prange JR Aj, Whybrow Pc, Noguera R(1972) Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry 26: 474 478

    Google Scholar 

  71. Dunner DL, Fieve RR(1975) Affective disorder: studies with amine precursors. Am J Psychiatry 132: 180–183

    PubMed  CAS  Google Scholar 

  72. Farinelli S et al(1991) Sindrome eosinofiliamialgia associata a 5-OH-triptofano Descrizione di un caso. Recenti Progressiv in Medicina 82: 7–8

    Google Scholar 

  73. Farkas T, Dunner Dl, Fieve Rr(1976) L-Tryptophan in depression. Biol Psychiatry 11: 295–302

    PubMed  CAS  Google Scholar 

  74. Glassman AH, Plattman SB(1969) Potentiation of a monoamine-oxidase inhibitor by tryptophan. J Psychiatr Res 7: 83–88

    PubMed  CAS  Google Scholar 

  75. Herrington Rn, Bruce A, Johnstone Ec(1976) Comparative trial of L-tryptophan and amitriptylin in depressive illness. Psychol Med 6: 673–678

    Google Scholar 

  76. Jensen K, Fruensgaard K, Ahlfors Ug(1975) Tryptophan/Imipramine in depression. Lancet 9: 920

    Google Scholar 

  77. Kirkegaard C, Moller SE, Bjorum N(1978) Additi-on of L-tryptophan to electroconvulsive treat- ment in endogenous depression. A double- blind study. Acta Psychiatr Scand 58: 457–462

    Google Scholar 

  78. Kline Ns, Sacks W(1963) Relief of depression within one day using an MAO inhibitor and intravenous 5-HTP. Am J Psychiatry 120: 274–275

    Google Scholar 

  79. Kline NS, Sacks W(1980) Treatment of depression with an MAO inhibitor followed by 5-HTP — an unfinished research project. Acta Psychiatr Scand [Suppl 2801: 233–241

    Google Scholar 

  80. Lindberg D, Ahlfors Ug, Dencker Sj(1979)Symptom reduction in depression after treatment with L-trypthophan or imipramine. Acta Psychiatr Scand 60: 287–294

    Google Scholar 

  81. Lopez-Ibor Ajj, Gutterriz I, Inglesias M(1973)Tryptophan and amitriptyline in the treatment of depression. IntPharmacopsychiatry 8: 145151

    Google Scholar 

  82. Lofez-Ibor JJ, Gutierrez JJA, Iglesias Mlmm(1976) 5-hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depres- sion. A double-blind controlled study. Int Pharmacopsychiatry 11: 8–15

    Google Scholar 

  83. Mendels J, Stinnet JL, Burns D, Frazer A(1975) Amine precursors and depressions. Arch Gen Psychiatry 32: 22–30

    PubMed  CAS  Google Scholar 

  84. Mendlewicz J, younim Mbh(1980) Antidepressant potentiation of 5-hydroxytryptophan by L-deprenyl in affective illness. J Affect Dis 2: 137–146

    PubMed  CAS  Google Scholar 

  85. Murphy DL, Baker m, goodwiN FK, Miller H, Kotin Jr, Bunney We(1974) L-Tryptophan in affective disorders. Indoleamine changes and differential clinical effects. Psychopharmacology 34: 11–20

    Google Scholar 

  86. Nardini M, De Stefano R, Iannuccelli M, Borghesi R, BattistininN (1983) Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharm Res 111: 239–250

    Google Scholar 

  87. Pope HE, JoNAS Jm, Hudson JI(1985) Toxic reactions to the combination of monoamineoxodase inhibitors and tryptophan. Am J Psychiatry 142: 491–492

    PubMed  Google Scholar 

  88. Praag Hm V(1978)Psychotropic drugs. A guide for the practitioner. Brunner/Mazel, New York, pp 280–281

    Google Scholar 

  89. Praag Hm V(1984) Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacol Bull 20: 599–602

    PubMed  Google Scholar 

  90. Praag Hm v, Korf J(1971) Endogenous depression with and without disturbances in the 5hydroxytryptamine metabolism: a biochemical classification? Psychopharmacologia 19: 148–152

    Google Scholar 

  91. Praag Hm V, De Haan S(1980) Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 3: 75–83

    PubMed  Google Scholar 

  92. Praag Hm V,Korf J, Dols Lcw, Schut T(1972) A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as an antidepressant. Psycho-pharmacology 25: 14–21

    Google Scholar 

  93. Quadbeck H, Lehmann E, Tegeler(1984) Com-parison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine. Neuropsychobiology 11: 111–115

    CAS  Google Scholar 

  94. Raleigh Mi(1987) Differential behavioral effects of tryptophan and 5-hydroxytryptophan in

    Google Scholar 

  95. vervet monkeys: influence of catecholaminergic systems. Psychopharmacology93: 44–50

    Google Scholar 

  96. Rao B, Broadhurst AD(1976) Tryptophan and depression. Br Med J 1: 460

    PubMed  CAS  Google Scholar 

  97. Raotma H(1978) Has tryptophan any anticonvul- sive effect. Acta Psychiatr Scand 57: 253–258

    PubMed  CAS  Google Scholar 

  98. De Smet Pagm(1991) Drugs used in non-ortho- dox medicine. In: Dukes Mng, Aronson JK (eds) Side effects of drugs, annual 15. Elsevier Science Publishers, Amsterdam, pp 514–531

    Google Scholar 

  99. Sourkes TL(1983) Toxicology of serotonin precursors. Adv Biol Psychiatry 10: 160–175

    CAS  Google Scholar 

  100. Thomas JM, Rubin EH(1984) Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatry 141: 281–283

    PubMed  CAS  Google Scholar 

  101. Thomson J, Rankin H, Ashcroft GW, Yates Cm, Mcqueen JK, Cummings SW(1982) The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med 12: 741751

    Google Scholar 

  102. Walinder J(1983) Combination of tryptophan with MAO inhibitors, tricycle antidepressants and selective 5-HT reuptake inhibitors. Biol Psychiatry 10: 82–93

    Google Scholar 

  103. Walinder J, Skott A, Nagy A(1976) Potentiation of antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry 33: 13841389

    Google Scholar 

  104. Weissman M, Fox R, Klerman JL(1973) Hostility and depression associated with suicide attempts. Am J Psychiatry 130: 450

    PubMed  CAS  Google Scholar 

  105. Woert Van Mh, Rosenbaum D, Howieson J,Bowers MB(1977) Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. N Engl J Med 296: 70–75

    Google Scholar 

  106. Worral EP, Moddy JP, Peet M, Dick P, Smith A, Chambers C, Adams M Naylor GJ(1979) Con-

    Google Scholar 

  107. trolled studies of the acute antidepressant ef- fects of lithium. Br J Psychiatry135: 255–262

    Google Scholar 

  108. Wurtman RJ, Hefti F, Mulamed E(1981) Precursor control of neuro-transmitter synthesis. Pharmacol Rev 32: 315–335

    Google Scholar 

  109. Young SN(1986) The clinical psychopharmacology of tryptophan. In: Wurtman RJ, Wurtman JJ (eds) Nutrition and the brain, vol 7. Raven, New York, pp 49–88

    Google Scholar 

  110. Zipp F, Demisch L(1992) Aktuelles in der Diskussion um das Eosinophilie-Myalgie-Syndrom ( Ems ). Nervenarzt 63: 249–253

    Google Scholar 

  111. Demisch L, HÖLZL J, Gollnik B, Kaczmarczyk P(1989) Idenditification of selective MAO- Type-A-Inhibitors in Hypericum Perforatum L. Pharmacopsychiatry 22: 194

    Google Scholar 

  112. Dietzel M(1990) Die Lichttherapie der endogenen Depression. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  113. Giese AC (1980) Hypericism. Photochem Photo-biol Rev 5: 229–255

    CAS  Google Scholar 

  114. Halama P (1991) Wirksamkeit des JohanniskrautExtraktes LI 160 bei depressiver Verstimmung. Nervenheilkunde 10: 250–253

    Google Scholar 

  115. Hansel R(1988) johanniskraut. In: St Einegger E, Hansel R (Hrsg) Lehrbuch der Pharmakognosie und Phytopharmazie, 4. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 672674

    Google Scholar 

  116. Harrer G, Schmidt U, Kuhn U(1991) „Alternative“ Depressionsbehandlung mit einem Hypericum-Extrakt. 1W Neurol Psych 5: 710–716

    Google Scholar 

  117. HÖLzL J(1989) Johanniskraut, eine alte Arzneipflanze mit neuer Bedeutung. Therapeutikon

    Google Scholar 

  118. -547

    Google Scholar 

  119. Hoffmann J, Kuhl Ed(1979) Therapie von depressiven Zuständen mit Hypericin. Z Allgemeinmed 55: 776–782

    CAS  Google Scholar 

  120. Johnson D(1991) Neurophysiologische Wirkungen von Hypericum im Doppelblindversuch mit Probanden. Nervenheilkunde 10: 316–317

    Google Scholar 

  121. Kniebel R, Burchard JN(1988) Zur Therapie depressiver Verstimmungen in der Praxis. Z Allgemeinmed 64: 689–696

    Google Scholar 

  122. könig C, Maier B(1992) Johanniskraut — der pflanzliche Stimmungsaufheller. Der informierte Arzt/Gazette Medicale 13: 1691–1694

    Google Scholar 

  123. Lehrl S, Woelk H(1991) Psychometrische Messung der Leistungskapazität unter antidepressiver Therapie mit Johanniskraut-Extrakt. Nervenheilkunde 10: 313–315

    Google Scholar 

  124. Monographie „Hyperics Herba“ Des Bundesge-Sundheitsamtes(1984) Bundesanzeiger Nr. 228 vom 5. 12. 1984

    Google Scholar 

  125. Müldner H, Zöller M(1984) Antidepressive Wirkung eines auf den Wirkstoffkomplex Hypercin standardisierten Hypericum-Extraktes. Arzneimittelforschung/Drug Res 34: 918920

    Google Scholar 

  126. Okpanyi SN, Weischer ML(1987) Tierexperimentelle Untersuchungen zur psychotropen Wirksamkeit eines Hypericum-Extraktes. Arzneimittelforschung/Drug Res 37: 10–13

    CAS  Google Scholar 

  127. Okpanyi SN, Lidzba H, Scholl BC, Miltenburger HG(1990) Genotoxizität eines standardisierten Hypericum-Extraktes. Arzneimittelforschung/Drug Res 40: 851–855

    CAS  Google Scholar 

  128. Panijel M(1985) Die Behandlung mittelschwerer Angstzustände. Therapiewoche 41: 46594668

    Google Scholar 

  129. Roth L(1990) Hypericum — Hypericin. Botanik, Inhaltsstoffe, Wirkung. ecomed, Landsberg

    Google Scholar 

  130. S135-138

    Google Scholar 

  131. Schimmer O, Häfele F, Krüger A(1988) The mU-tagenis potencies of plant extracts containing quercetin in Salmonella typhimurium TA98 und TA100. Mutat Res 206: 201–208

    PubMed  CAS  Google Scholar 

  132. Schlich D, Braukmann F, SchenkN (1987) Behandlung depressiver Zustandsbilder mit Hypericinium. Psycho 13: 440–447

    Google Scholar 

  133. Schmidt U (1989) Zur Therapie depressiver Verstimmungen. Psycho 15: 665–671

    Google Scholar 

  134. Siegers CP, Steffen B(1991) influence of querce-tin on cell proliferation and DNA-synthesis in human tumor cell lines. Pharma Pharmacol Lett 1: 64–67

    Google Scholar 

  135. Sommer H(1991) Besserung psychovegetativer Beschwerden durch Hypericum im Rahmen einer multizentrischen Doppelblindstudie. Nervenheilkunde 10: 308–310

    Google Scholar 

  136. Steger W(1985) Depressive Verstimmungen. Z Allgemeinmed 61: 914–918

    Google Scholar 

  137. Stock S, Hölzl J(1991) Pharmacokinetic test of (14C)- labelled hypericin and pseudohypericin from hypericum perforatum and serum kinetics of hypericin in man (39th Annual Con-gress on Medicinal Plant Research, Abstracts, p 70 ). Thieme, Stuttgart, pp 61–62

    Google Scholar 

  138. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H(1984) Inhibition of monoamine oxidase by hypericin. Planta Med 50: 272–274

    PubMed  CAS  Google Scholar 

  139. Weiser D(1991) Pharmakokinetik von Hypericin nach oraler Einnahme des JohanniskrautExtraktes LI 160. Nervenheilkunde 10: 318–319

    Google Scholar 

  140. Wichtl M(1983) Hypericum perforatum L. — Johanniskraut. Wissenschaftliches Gutachten als Grundlage der Monographie „Hyperici herba“ des Bundesgesundheitsamtes

    Google Scholar 

  141. Wichtl M(1989) Johanniskraut. In: WICHTL M (Hrsg) Teedrogen. Ein Handbuch für die Praxis auf wissenschaftlicher Grundlage. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 257–259

    Google Scholar 

Download references

Authors
  1. L. Demisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Bruinvels
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Nedopil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Schulz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Hänsel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Psychiatrische Universitätsklinik, Füchsleinstraße 15, D-97080, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Psychiatrische Universitätsklinik, Sigmund-Freud-Straße 25, D-53105, Bonn, Bundesrepublik Deutschland

    Gerd Laux

  3. Psychiatrische Universitätsklinik, Wilhelm Klein-Straße 27, CH-4025, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Wien

About this chapter

Cite this chapter

Demisch, L., Bruinvels, J., Kasper, S., Nedopil, N., Schulz, V., Hänsel, R. (1993). Präkursoren. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3317-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3317-0_7

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3318-7

  • Online ISBN: 978-3-7091-3317-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation